FDA Panel To Weigh DXM Education, Sales Restrictions Against Scheduling
This article was originally published in The Tan Sheet
Executive Summary
The continued availability of OTC dextromethorphan depends on convincing safety experts that less restrictive measures than scheduling DXM as a controlled substance will sufficiently reduce abuse